Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 plus atezolizumab in advanced mismatch repair proficient oesophagogastric cancer
2018-004138-13Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirexatamab and atezolizumab in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Safe and tolerated dose and Radiological response. Status: unknown.
02
Drugs
sirexatamabatezolizumab
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2018-004138-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004138-13.